Three-hydroxy-3-methyl glutaryl co-enzyme A (HMG-CoA) reductase inhibitors, also known as statins, are widely used therapeutic agents in atherosclerosis and act by reducing circulating LDL levels through effects on hepatic LDL clearance. This evidence concerns the gene HMGCR and atherosclerosis.